Johnson & Johnson (NYSE: JNJ) is scheduled to announce its fourth-quarter earnings results before the market opens on Wednesday, January 21. This upcoming earnings report comes amid expectations of earnings growth and revenue expansion compared to the same quarter last year.
Analysts following the healthcare conglomerate project an earnings per share (EPS) figure of $2.47 for the fourth quarter. This estimate marks an improvement over the $2.04 per share that the company posted during the corresponding period last year. Concurrently, the consensus revenue forecast stands at $24.16 billion, which is higher than the $22.52 billion recorded in the prior year’s quarter, according to data sourced from Benzinga Pro.
In the period leading up to the earnings announcement, Johnson & Johnson disclosed key clinical data from late-stage research initiatives. On January 14, the company revealed preliminary topline results from the investigational Phase 3 MajesTEC-9 clinical trial evaluating Tecvayli (teclistamab-cqyv) as a single-agent treatment for multiple myeloma, a hematologic cancer. These findings are highly anticipated given their potential impact on future growth in the pharmaceutical segment.
In terms of market performance, Johnson & Johnson’s shares experienced a marginal decline of 0.2%, closing at $218.21 on the trading day prior to the earnings release. This modest movement reflects investor caution ahead of the detailed financial disclosures.
Recent Analyst Price Target Revisions and Ratings
A survey of recent analyst commentary from leading Wall Street firms highlights a generally positive outlook with several price target increases, despite mixed rating stances.
- Bernstein: Analyst Lee Hambright affirmed a Market Perform rating on January 9, 2026, while raising the price target from $193 to $208. Hambright’s evaluations carry an accuracy rate of 59%.
- Barclays: Matt Miksic maintained an Equal-Weight rating as of December 30, 2025, simultaneously boosting the target price from $197 to $217. The analyst has a historical accuracy of 65%.
- Goldman Sachs: Asad Haider retained a Buy rating dated December 19, 2025, and raised the price target notably from $213 to $240. Haider’s forecast accuracy stands at 68%.
- B of A Securities: Analyst Tim Anderson upheld a Neutral rating on December 15, 2025, while increasing the price target from $204 to $220. The analyst’s accuracy is recorded at 66%.
- Morgan Stanley: Terence Flynn held an Equal-Weight rating with a revised target price of $197, up from $190, on December 12, 2025. Flynn’s accuracy rate is among the highest at 72%.
Outlook and Market Positioning
These price target adjustments underscore expectations that Johnson & Johnson may deliver performance improvements, although analyst opinions range between neutral and buy recommendations. This gradient of sentiment suggests investor considerations around the balance of growth potential and valuation.
Investors interested in JNJ shares are advised to consider the detailed price targets, rating rationales, and analyst accuracy to better gauge the risks and opportunities ahead of the earnings release.
Additional Market Insights
Separately, Benzinga’s data indicates that top-performing stocks for the coming year typically exhibit a blend of value, momentum, and quality metrics. Some names on the list have already demonstrated significant gains, signaling the importance of comprehensive stock evaluation methodologies.
Johnson & Johnson closed recently at $217.50, showing a slight decrease of 0.33%. Current market metrics—including momentum, growth, quality, and value scores—are accessible through specialized platforms for those conducting a granular assessment of the stock’s positioning.
Conclusion
As Johnson & Johnson approaches its fourth-quarter earnings announcement, the company is under close scrutiny for its financial results and clinical research progress. Analyst expectations point to year-over-year growth in key metrics, with revised price targets reflecting varying degrees of optimism. The market reaction and detailed earnings disclosures will provide further clarity on the company’s trajectory heading into 2026.